SCHEMBL6630359

SCHEMBL6630359

CCN(C(=O)On1ccc(-c2ccc([N+](=O)[O-])cc2)n1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
SCN4A P35499 1/20 0.43
CRHBP P24387 2/20 0.42
CRHR2 Q13324 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
TLR9 Q9NR96 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
PHGDH O43175 1/20 0.38
AR P10275 2/20 0.37
GLA P06280 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650068 0.86 ALDH1A1 (0.55) ALDH1A1SCN4ACRHBPCRHR2SMN1; SMN2
SCHEMBL6632687 0.75 AURKA (0.47) ALDH1A1SCN4ARAB9AMEN1KMT2A
SCHEMBL6631235 0.72 RORC (0.43) ALDH1A1SCN4ASMN1; SMN2MEN1KMT2A
SCHEMBL5648908 0.71 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2
SCHEMBL29280745 0.69 ALDH1A1 (0.62) ALDH1A1CRHBPCRHR2SMN1; SMN2RAB9A
SCHEMBL7376588 0.69 ALDH1A1 (0.89) ALDH1A1CRHBPCRHR2SMN1; SMN2TRPM8
SCHEMBL5649534 0.69 LIPE (0.47) ALDH1A1SCN4ASMN1; SMN2RAB9AMEN1
SCHEMBL5651163 0.69 SCN4A (0.47) ALDH1A1SCN4ASMN1; SMN2RAB9AMEN1
SCHEMBL5645237 0.69 ALDH1A1 (0.44) ALDH1A1CRHBPCRHR2SMN1; SMN2RAB9A
SCHEMBL5646425 0.68 AKR1C3 (0.47) ALDH1A1SCN4ASMN1; SMN2RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL ALDH1A1 1304/4885SCN4A 4707/4885CRHBP 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.